Extracorporeal Photopheresis

Extracorporeal Photopheresis

EXTRACORPOREAL PHOTOPHERESIS (ECP) involves the immunomodulation of Multiple Sclerosis disease progression. Over the years, ECP has been introduced as a therapeutic option for cutaneous T-cell lymphoma (CTCL), graft versus host disease (GvHD), and it has been investigated as a preventive measure to reduce the risk of heart, lung, and kidney transplant rejection, and in other conditions, including autoimmune and sclerosing disorders. The therapeutic mechanisms triggered by ECP involve immunostimulatory, immunosuppressive, and immunotolerizing effects. The ADSCC Research Team has planned to verify the safety and efficacy of ECP in MS adult patients.